Senti Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary

Senti Biosciences (Nasdaq: SNTI) announced that on Dec 12, 2025 its board granted inducement stock options to one new employee to purchase 13,680 shares at an exercise price of $1.31 per share. The awards were granted under the company's Amended and Restated 2022 Inducement Equity Plan and were described as material inducements under Nasdaq Listing Rule 5635(c)(4). The Plan was initially adopted by the board on Aug 5, 2022. No additional financial guidance, vesting schedule, or dilutive impact was disclosed in the announcement.

Key Figures

Inducement options granted 13,680 shares Stock options to one new employee effective December 12, 2025

Option exercise price $1.31 per share Exercise price for inducement stock options

Plan adoption date August 5, 2022 Amended and Restated 2022 Inducement Equity Plan board adoption

NASDAQ rule Rule 5635(c)(4) Basis for inducement grant exemption from shareholder approval

Market Reality Check

$1.22 Last Close

Volume Volume 543,724 is well below the 4,405,951 share 20-day average, indicating muted trading interest pre‑announcement. low

Technical Shares at $1.17 are trading below the $2.36 200-day moving average and 78.49% under the 52-week high.

Peers on Argus 1 Up

SNTI was down 2.4% while close peers showed mixed moves: LSB down 20.62%, LVTX down 3.87%, MRSN up 0.24%, and IPSC up 12.43%. This points to stock-specific, not sector-wide, trading.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 09	Regulatory designation	Positive	-35.6%	FDA RMAT designation for SENTI-202 in R/R AML patients.
Dec 09	Clinical data update	Positive	-35.6%	Updated Phase 1 SENTI-202 data with strong ORR and CR/CRh rates.
Dec 04	Conference call/webcast	Positive	+0.9%	Announcement of ASH webcast to discuss SENTI-202 clinical data.
Nov 13	Earnings and pipeline	Negative	-5.3%	Q3 2025 loss of <b>$18.1M</b> and low cash balance disclosure.
Nov 03	Conference presentation	Positive	-1.5%	Announcement of updated SENTI-202 ASH presentations with positive signals.

Pattern Detected

Recent history shows several sharp negative price reactions (down to -35.56%) even on seemingly positive clinical and regulatory updates, indicating a tendency for the stock to sell off around major news.

Recent Company History

Over the last few months, Senti Bio has focused on SENTI-202 clinical progress and financial updates. In November 2025, Q3 results highlighted a $18.1M net loss and low cash, followed by multiple ASH-related SENTI-202 data disclosures in early December 2025. Despite positive signals such as RMAT designation and strong response rates, shares fell as much as 35.56% after the December 9 announcements. Today’s small inducement option grant fits into a pattern of routine equity compensation against a backdrop of clinically active but market-challenged trading.

Market Pulse Summary

This announcement details a small inducement option grant of 13,680 shares at $1.31 per share under the 2022 Inducement Equity Plan, made in line with NASDAQ Listing Rule 5635(c)(4). Set against prior updates—such as SENTI-202’s RMAT designation and a Q3 2025 net loss of $18.1M—the news reflects routine equity-based hiring rather than a strategic shift. Investors may monitor future clinical milestones, financing developments, and additional compensation grants for indications of execution and dilution risk.

Key Terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that effective December 12, 2025 Senti Bio’s Board of Directors granted to one new employee stock options to purchase an aggregate of 13,680 shares of the Company’s common stock with a per share exercise price of $1.31 per share. These awards were made under the Company’s Amended and Restated 2022 Inducement Equity Plan (the “Plan”).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was initially adopted by the Company’s board of directors on August 5, 2022.

About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.

Availability of Other Information About Senti Bio
For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on X (formerly Twitter) (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com

FAQ

What stock option grant did Senti Biosciences (SNTI) announce on Dec 18, 2025?

The company disclosed board-approved inducement options for one new employee to buy 13,680 shares at $1.31 per share, effective Dec 12, 2025.

Under which plan were the SNTI inducement awards granted and when was it adopted?

Awards were granted under the Amended and Restated 2022 Inducement Equity Plan, initially adopted Aug 5, 2022.

What Nasdaq rule did Senti cite for the inducement grant for SNTI?

The grants were described as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

How many shares and at what exercise price were granted in the SNTI inducement?

An aggregate of 13,680 shares were granted with a per-share exercise price of $1.31.

Does the announcement for SNTI disclose vesting terms or dilution impact?

No; the release does not disclose vesting schedules or quantify potential dilution or outstanding share count.